Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients

Journal of Viral Hepatitis

Volumn 14, Issue 12, 2007, Pages 835-840

  Jardi, R ^a   Rodriguez Frias, F ^a   Schaper, M ^a   Ruiz, G ^a   Elefsiniotis, I ^a   Esteban, R ^a   Buti, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Chronic hepatitis B; Drug resistance; Entecavir therapy; Hepatitis B virus; Lamivudine therapy

Indexed keywords

ENTECAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; BLOOD SAMPLING; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; RETROSPECTIVE STUDIES; RNA-DIRECTED DNA POLYMERASE;

EID: 36749040378     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00877.x     Document Type: Article

References (19)

1. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of a BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997 41 : 1444 1448.
2. Zoulim F. Entecavir: A new treatment option for chronic hepatitis B. J Clin Virol 2006 36 : 8 12.
3. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004 48 : 3498 3507.
4. Levine S, Hernández D, Yamanaka G et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinan polymerases in vitro. Antimicrob Agents Chemother 2002 46 : 2525 2532.
5. Durantel D, Brunelle MN, Gros E et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 2005 34 : S34 S43.
6. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006 78 : S52 S55.
7. Chang TT, Gish RG, Man R et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006 354 : 1001 1010.
8. Colonno RJ, Rose RE, Levine SM et al. Entecavir (ETV) resistance is not observed in nucleoside naive subjects and is observed infrequently by week 48 in lamivudine refractory subjects with chronic HBV infection. J Hepatol 2005 42 (Suppl. 2 A478.
9. Chang TT, Gish RG, Hadziyannis SJ et al. A dose ranging study of the efficacy and tolerability of entecavir in lamivudine refractory chronic hepatitis B patients. Gastroenterology 2005 129 : 1198 1209.
10. Lai ChL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients HBeAg negative chronic hepatitis B. N Engl J Med 2006 354 : 1011 1020.
11. Shermann M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine refractory HBeAg positive chronic hepatitis B. Gastroenterology 2006 130 : 2039 2049.
12. Jardi R, Rodriguez F, Buti M et al. Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat 2001 8 : 465 471.
13. Rodriguez F, Buti M, Jardi R et al. Hepatitis B virus infection. Precore mutants and its relation to viral genotypes. Hepatology 1995 22 : 1641 1647.
14. Colonno RJ, Rose R, Levine SM et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II and III studies is only observed in lamivudine refractory patients. Hepatology 2004 40 (Suppl. 1 661A.
15. Shouval D, Acara US, Hatzis G et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg negative chronic hepatitis B patients (study 027). J Hepatol 2005 44 (Suppl. 2 S21.
16. Yurdaydin C, Sollanno J, Hadziyannis S et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion to 96 weeks of treatment in lamivudine- refractory HBeAg positive chronic hepatitis B patients (ETV 026). J Hepatol 2005 44 (Suppl. 2 S36.
17. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001 34 : 584 586.
18. Najera I, Holguin A, Quiñones-Mateu ME et al. Pol Gen quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995 69 : 23 31.
19. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resitance is rare in naïve patients with hepatitis B. Hepatology 2006 44 : 1656 1665.